CYTOKINETICS INC Form 8-K December 03, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

December 3, 2007

Cytokinetics, Incorporated

(Exact name of registrant as specified in its charter)

Delaware	000-50633	94-3291317
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
280 East Grand Avenue, South San Francisco, California		94080
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including area coc	le:	(650) 624 - 3000
	Not Applicable	
Former name or for	rmer address, if changed since	ast report
Check the appropriate box below if the Form 8-K filing is inte the following provisions:	ended to simultaneously satisfy	the filing obligation of the registrant under any o
[] Written communications pursuant to Rule 425 under the S [] Soliciting material pursuant to Rule 14a-12 under the Exc	*	<i>*</i>

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form Item 8.01 Other Events.

On December 3, 2007, Cytokinetics, Incorporated issued a press release announcing a presentation of preclinical data relating to CK-1827452, a novel small molecule activator of cardiac myosin, at the 47th Annual American Society of Cell Biology meeting in Washington, DC. CK-1827452 is being evaluated in clinical trials for the potential treatment of heart failure and is the subject of a Collaboration and Option Agreement between Cytokinetics and Amgen Inc. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following Exhibit is filed as part of the Current Report on Form 8K:

Exhibit No. Description

99.1 Press Release, dated December 3, 2007.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cytokinetics, Incorporated

December 3, 2007 By: /s/ Sharon Surrey-Barbari

Name: Sharon Surrey-Barbari

Title: Senior Vice President, Finance and Chief Financial

Officer

Top of the Form

Exhibit Index

Exhibit No.	Description				
99.1	Press release, dated December 3, 2007				

94,089 I By spouse

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8	5. tionNumber of) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	3	ate	7. Tit Amou Under Secur (Instr	int of rlying	8. Price of Derivative Security (Instr. 5)	
				Code '	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
TEETS RICHARD P JR						

7575 W. JEFFERSON BLVD. X FORT WAYNE, IN 46804

Signatures

Richard P. 08/21/2017 Teets, Jr.

**Signature of Date Reporting Person

Reporting Owners 5

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents the number of shares of common stock underlying deferred stock units (DSUs) issued to the reporting person in connection with a portion of this person's retainer as a director under the Steel Dynamics, Inc. 2015 Equity Incentive Plan. This transaction is exempt from the provisions of Section 16(b), by virtue of Rule 16b-3(d)(1) and (3).
 - Reportable as directly owned shares of common stock, rather than as a derivative security in Table II, because any and all underlying
- (2) DSUs are payable, at such time as they are to be settled, solely in shares of common stock. (See Lincoln National Corp. (March 20, 1992) (Q.3).
- (3) Includes shares resulting from reinvestment of dividends on any underlying DSUs included in this total.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.